Literature DB >> 9825805

Regulated and endothelial cell-specific expression of Fas ligand: an in vitro model for a strategy aiming at inhibiting xenograft rejection.

T H Tran1, S Grey, J Anrather, F Steinhäuslin, F H Bach, H Winkler.   

Abstract

BACKGROUND: Immunologically privileged sites have been shown to express Fas ligand (FasL) and may protect themselves by inducing apoptosis of infiltrating inflammatory cells. We asked whether the Fas/FasL interaction could be used to protect a xenograft from rejection. We proposed that endothelial cells that are resistant to Fas-mediated killing could be considered as a vehicle for expression of recombinant FasL.
METHODS: Based on the tetracycline-regulated expression system, constructs were designed that allow endothelial cell-specific and regulated expression of FasL by placing the tetracycline-dependent transactivator under control of the murine intercellular adhesion molecule-2 promoter.
RESULTS: Primary bovine endothelial cells transfected with FasL efficiently killed Fas-expressing cells in a regulated manner. Not only Fas-positive cell lines but also human peripheral blood lymphocytes underwent apoptosis upon exposure to FasL-transfected endothelial cells.
CONCLUSION: This in vitro model may provide tools for the generation of transgenic animals to be used as donors for vascularized xenograft transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825805     DOI: 10.1097/00007890-199811150-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  An in vivo model of hyperacute rejection: characterization and evaluation of the effect of transgenic human complement inhibitors.

Authors:  M Mora; M Lazzer; G Marsicano; L C Mulder; L Carraresi; A Pieri; A Benanchi; D Grifoni; S Nuti; P Bruzzone; M Comporti; R Cortesini; M Rossini
Journal:  Transgenic Res       Date:  2000-06       Impact factor: 2.788

2.  Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes.

Authors:  Esma S Yolcu; Haval Shirwan; Nadir Askenasy
Journal:  Front Immunol       Date:  2017-03-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.